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Abstract 22 
Non-ionic surfactant vesicles (NISV) are colloidal particles that provide a useful delivery 23 
system for drugs and vaccines. One of the methods that is used for NISV preparation is 24 
microfluidics in which the lipid components dissolved in organic phase are mixed with an 25 
aqueous medium to prepare the particles through self-assembly of the lipids. In this work, we 26 
examined the effect of using different types of aqueous media on the characteristics of the 27 
NISV prepared by microfluidics. Five aqueous media were tested: phosphate buffered saline, 28 
HEPES buffer, Tris buffer, normal saline and distilled water. The resulting particles were tested 29 
for their physical characteristics and cytotoxicity. The aqueous media were found to have 30 
significant effects on the physical characteristics of the particles, as well as their overall 31 
stability under different conditions and their cytotoxicity to different human cell lines. Careful 32 
consideration should be taken when choosing the aqueous media for preparing NISV through 33 
microfluidics. This is an important factor that will also have implications with respect to the 34 
entrapped material, but which in addition may help to design vesicles for different uses based 35 
on changing the preparation medium. 36 
Key Words 37 
Non-ionic surfactant vesicles, Microfluidics, Hydration media, Drug delivery 38 
1. Introduction:  39 
Non-ionic surfactant vesicles (NISV) are synthetic vesicles constructed through the self-40 
assembly of hydrated non-ionic surfactants with cholesterol and other additives, into a bilayer 41 
structure enclosing an aqueous core. In terms of physical properties and structure, NISV are 42 
similar to liposomes, which are the most commonly used lipid particles as drug delivery 43 
systems [1]. NISV were first reported by the cosmetic company /¶2UpDO in the 1980s and since 44 
then they have gained in interest as a drug delivery system, as they offer more advantages 45 
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compared with liposomes in terms of lipid cost and stability [1, 2]. Non-ionic surfactants are 46 
the basic components of NISV. These surfactants are amphiphilic molecules with both a 47 
hydrophilic (water soluble) head and hydrophobic (organic soluble) tail with no charged 48 
groups in their hydrophilic heads [3]. The bilayer structure of the NISV makes them capable 49 
of encapsulating both hydrophilic and hydrophobic substances. Hydrophilic substances are 50 
thought to be encapsulated in their aqueous core or adsorbed on the bilayer surface, while 51 
hydrophobic substances are embedded into the lipophilic domain of the bilayer [3].  52 
Surfactants commonly used to prepare NISV include polyoxyethylene fatty acid esters 53 
(Tweens), sorbitan fatty acid esters (Spans), alkyl ethers, and alkyl glyceryl ethers (Brijs) 54 
[4]. The most common additive in a NISV formulation is cholesterol, which affects the 55 
membrane structure and the physical properties of the vesicles [5] and its most 56 
important effect is the modulation of the mechanical strength of the bilayer structure and 57 
water permeability [6, 7]. Moreover, cholesterol incorporation tends to enhance drug 58 
entrapment efficiency, vesicle stability, and can modulate drug release in the NISV 59 
formulations [8, 9]. Other additives include charged molecules to enhance the stability of 60 
the NISV formulations during storage and prevent vesicle aggregation by electrostatic 61 
repulsion. Dicetyl phosphate (DCP) and phosphatidic acids are used to impart a negative 62 
charge on the surface of the NISV, while cationic molecules such as stearylamine and 63 
cetylpyridinium chloride are used to provide a positive charge on the vesicles [1, 3]. Due 64 
to their potential to carry and encapsulate a variety of drugs, NISV have been widely used 65 
to deliver drugs to specific target sites, to control drug release and enhance permeation. 66 
They have been investigated as a potential drug delivery system for anticancer [10, 11], 67 
anti-inflammatory and anti-infective drugs [12, 13], peptides [14, 15], transdermal drug 68 
delivery [16, 17] and gene delivery [18].   69 
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Numerous methods for NISV preparation are reported. The thin-film hydration method 70 
(TFH) is simple and widely used. The surfactants and other additives are dissolved in 71 
organic solvent in a round-bottomed flask. The organic solvent is then removed using a 72 
rotary vacuum evaporator to form a thin film of lipids on the wall of the flask, which is 73 
then hydrated by the addition of an aqueous solution with or without drug to form multi-74 
lamellar vesicles [3, 19]. In the reverse-phase evaporation (REV) method, after 75 
evaporating the organic solvent as in the TFH method, the dried lipid film is purged with 76 
nitrogen and the lipids are re-dissolved with a second organic phase of diethyl ether 77 
and/or isopropyl ether followed by the addition of aqueous mixture to form large 78 
multilamellar vesicles and then the organic solvent is removed under reduced pressure 79 
by rotary evaporation [20, 21]. In the organic injection method, the organic solvent 80 
containing the dissolved surfactants and other additives is slowly injected through a 81 
needle in an aqueous solution to form NISV of various sizes [22].  Other methods include 82 Ǯǯǯǯǡ and freeze-thaw methods [3]. However, in most of these, the local 83 
chemical and/or mechanical environments are not well controlled and the vesicles that 84 
are formed are large with considerable size polydispersity, which requires a suitable 85 
post-preparation size reduction step e.g. by sonication or extrusion, to obtain small and 86 
homogeneous vesicles [23]. More recently, a microfluidic method has been employed for 87 
the preparation of lipid-based nanoparticles that uses microfluidic hydrodynamic focusing and 88 
has been shown to produce small sized nanoparticles for drug encapsulation [24]. In this 89 
method, the surfactants and other additives dissolved in an organic phase, are mixed with an 90 
aqueous phase at high flow rates and passed through a precisely defined microchannel at a 91 
temperature above the phase transition of the lipids. Factors such as flow rate ratios (FRR) 92 
between the aqueous and organic phases and the total flow rates (TFR) of both phases can be 93 
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controlled during the mixing process to prepare homogeneous small particles in a single step 94 
[25, 26].  95 
All of the above mentioned methods involve the hydration of the surfactant and lipid 96 
mixtures with an aqueous phase at elevated temperature, followed by an optional size 97 
reduction with some preparation methods [27]. Phosphate buffered saline (PBS) is a 98 
common buffer used for NISV preparation. It is an ionic buffer composed of sodium chloride, 99 
sodium phosphate, and (in some formulations) potassium chloride and potassium phosphate 100 
and has a pH range from 5.8-8.0 at 25°C [28]. PBS is the preferred buffer for particle formation 101 
because the osmolarity and ion concentrations match those of human body fluids such as blood 102 
[29]. Other buffers such as (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), 103 
Tris, citrate and carbonate can also be used [30, 31]. NISV can also be prepared using distilled 104 
water (DW) as an aqueous media. However, it is imperative to select an optimal buffer system 105 
for drug encapsulation in NISV. For example, phosphate and citrate buffers are not 106 
recommended for components that contain calcium ions, as phosphate forms an insoluble 107 
calcium phosphate precipitate, while citric acid chelates calcium [32]. Tris buffer is used for 108 
the storage of nucleic acids and is suitable for formulating NISV where nucleic acids are being 109 
encapsulated. However, Tris can interfere in vivo and in vitro with copper by chelation and can 110 
act as a competitive inhibitor to some enzymes [32, 33]. 111 
In the present work, we investigated the effect of five different aqueous media on the 112 
characteristics of empty NISV. Given that previous work from our lab has investigated the use 113 
of NISV for vaccine delivery using a surfactant combination of monopalmitin glycerol 114 
(MPG):cholesterol (Chol): dicetyl phosphate (DCP) at a molar ratio of 50:40:10 [34, 35], we 115 
have used this formula as a model to examine the various physicochemical aspects of vesicles 116 
composed with these lipid components, but prepared using five different aqueous media and 117 
using a microfluidic mixing method of preparation. In vitro cytotoxicity experiments were 118 
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subsequently performed to evaluate the effect of the different formulations resulting from the 119 
use of the different hydrating media on human A375 (skin malignant melanoma), A2780 120 
(ovarian carcinoma) and PNT2 (normal prostate epithelium) cells.  121 
2. Materials and methods 122 
2.1 Materials 123 
MPG was purchased from Larodan Fine Chemicals AB (Sweden). Chol, DCP, resazurin 124 
powder, PBS tablets, HEPES buffer solution, Tris buffer solution, sodium hydrochloride 125 
(NaCl), serum-free and antibiotic-free medium Roswell Park Memorial Institute medium 126 
(RPMI 1640), L-glutamine, penicillin±streptomycin, and foetal bovine serum (FBS) were 127 
purchased from Sigma-Aldrich (UK). The human cell lines A375, A2780, and PNT2 were 128 
purchased from American Type Culture Collection (ATCC®) and kindly provided by Mrs 129 
Louise Young, (University of Strathclyde). 130 
2.2 NISV preparation by microfluidics with different hydration media 131 
NISV were prepared by employing a microfluidic micromixer as described elsewhere [24]. The 132 
hydration media used to prepare the vesicles were PBS (10 mM, pH 7.4), HEPES buffer (10 133 
mM, pH 7.4), Tris buffer (10 mM, pH 7.4), 0.9% (w/v) normal saline (NS) and DW. An ethanol 134 
solution containing MPG, Chol, and DCP at a molar ratio of 50:40:10 was prepared at a 135 
concentration of 10 mg/ml total lipids.  The microfluidic apparatus used was the 136 
NanoAssemblrTM BenchtopTM (Precision NanoSystems Inc., Vancouver, Canada) which 137 
enables a controlled nanoprecipitation process by hydrodynamic flow, focused through a two-138 
channel microfluidic system. 139 
For the preparation of empty vesicles, a specific volume of each of the tested hydration media 140 
was mixed with the lipid phase in ethanol at a volumetric flow rate of 3:1 (aqueous: lipid) in 141 
the microfluidic micromixer at a total flow rate of 12 mL/minute (9 mL/minute for the aqueous 142 
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phase and 3 mL/minute for the lipid phase) at 50ºC. The mixed materials, upon leaving the 143 
micromixer outlet, was diluted into an equal volume of the aqueous media used in the 144 
preparation in order to reduce the ethanol content in the final preparation to 12.5%. The NISV 145 
mixture was then dialysed overnight against 1000 volumes of aqueous media used in the vesicle 146 
preparation using 6QDNH6NLQ 'LDO\VLV 7XELQJ (10,000 Da molecular weight cut off; 147 
Thermofisher Scientific, UK) at 25°C. 148 
2.3 Particle size, polydispersity and charge of NISV prepared with different hydration 149 
media 150 
Particle size, polydispersity index (PDI) and zeta potential (ZP) were measured with a Zetasizer 151 
Nano-ZS (Malvern Instruments, UK). The measurements were carried out for NISV prepared 152 
in each hydration media at 25°C at a 1/20 dilution. All samples were prepared in triplicate and 153 
the ZAverage, PDI, and ZP reported. 154 
2.4 Stability of NISV at different temperatures 155 
Stability of the NISV was evaluated over two months at 4, 25, 37, and 50 °C in controlled 156 
temperature rooms over the duration of the study. Size, PDI and zeta potential were measured 157 
at different time points (0, 1, 2, 3, 4, 6 and 8 weeks).  158 
2.5 Morphological analysis of NISV using scanning electron microscopy 159 
Morphological analysis of the NISV was carried out using a FEI Quanta 250 field emission 160 
variable pressure scanning electron microscope (SEM) (FEI, Oregon, USA) equipped with an 161 
Everhart±Thornley type detector and running FEI software. Each sample of NISV was diluted 162 
ZLWKWKHPHGLDXVHGLQWKHIRUPXODWLRQDQGȝORIeach diluted sample was dried on a 163 
silicon substrate and placed under vacuum. An accelerating voltage of 5 kV was applied to 164 
each sample in high vacuum mode and secondary electron images were collected. 165 
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2.6 High Performance Liquid Chromatography (HPLC) analysis of cholesterol content 166 
of NISV  167 
In order to assess the concentration of the NISV produced and to determine the yield and 168 
preparation efficacy, NISV were analysed using HPLC to measure the quantity of cholesterol 169 
present post-preparation. HPLC was performed using an Agilent Technologies 1260 Series 170 
Liquid Chromatography system controlled by Clarity Chromatography software. The 171 
conditions of the run were as follows: mobile phase acetonitrile:methanol:2-propanol; (7:3:1, 172 
v/v/v), flow rate 1 mL/min, total run time 10 min; column YMCbasic C18, 250 X 3.0 mm, 173 
column temperature 60ºC, injection volume 20 µL, detection 205 nm, retention time 1.55 min. 174 
A standard curve of Chol (31.25 ± 1000 µg/ml) was constructed by measuring the area under 175 
the curve (AUC). NISV prepared were lysed with isopropyl alcohol (50%, v/v) and then 176 
analysed by HPLC as previously described [36]. The Chol concentration was determined by 177 
measuring the AUC and calculating the concentration using the equation generated from the 178 
standard curve. 179 
2.7 Turbidity assay  180 
To understand NISV behaviour under physiological conditions, the aggregation tendency of 181 
the NISV was studied using a turbidity assay [37]. FBS was added to each NISV formulation 182 
to a final concentration of 10% (v/v) in each hydration medium. This concentration of FBS was 183 
chosen as it is generally used for in vitro studies. Turbidity was determined by measuring the 184 
absorbance at 298 nm using a HELIOS ALPHA ThermoSpectronic spectrophotometer using 185 
serum alone as a background [37]. NISV (625 µg/ml) were incubated at 37 °C and analysed 186 
over a 2 h time period. Relative turbidity was calculated by dividing sample absorbance at a 187 
specific time by the time zero value incubated in the corresponding hydration buffer used for 188 
NISV preparation. 189 
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2.8 Cytotoxicity of NISV evaluated using a number of human cell lines 190 
NISV were assessed for cytotoxicity on three different cell lines (A375, A2780, and PNT2). 191 
Each cell line was seeded in a 96-well plate at a density of 1×104
 
per well in 100µl and 192 
incubated for 24 h at 37°C, 5% CO2 and 100% humidity in RPMI 1640 medium supplemented 193 
with 10% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) penicillin-streptomycin. After 24 h, 194 
cells were treated with different concentrations of NISV (9.77-1250 µg/mL). Dimethyl 195 
sulphoxide (DMSO) was used as a positive kill control and one column per plate contained 196 
untreated cells and medium.  Each of the hydration buffers without the particles was also 197 
included to ensure that the media itself are not toxic. The plates were then incubated for a 198 
further 24 h and then 20 µl of resazurin (0.1 mg/ml) was added to each well and incubated for 199 
a further 24 h.  Resazurin is bio-reduced by viable cells from blue into a pink resorufin product, 200 
which indicates the presence of metabolically active cells and results in both a colorimetric and 201 
fluorometric change. After 24 h, the quantity of resorufin was measured on a SpectraMax M5 202 
plate reader (Molecular Devices, Sunnyvale, CA, USA) at 560 nm - 590 nm. The absorbance 203 
reading at this wavelength is directly proportional to the number of metabolising cells in the 204 
medium. In this study, cell viability was calculated and expressed as a percentage of the 205 
positive control (i.e., untreated cells):  206 
 ? ൌ  ቀ୅ୠୱ୭୰ୠୟ୬ୡୣ୭୤ୡୣ୪୪ୱ୲୰ୣୟ୲ୣୢ୵୧୲୦୒୍ୗ୚ୟ୲ ஛ୣ୶ ୀ ହ଺଴ ୬୫ǡ ஛ୣ୫ ୀ ହଽ଴ ୬୫୅ୠୱ୭୰ୠୟ୬ୡୣ୭୤୳୬୲୰ୣୟ୲ୣୢୡୣ୪୪ୱ ஛ୣ୶ ୀ ହ଺଴ ୬୫ǡ ஛ୣ୫ ୀ ହଽ଴ ୬୫ ቁ  ? ? ? 207 
2.9 statistical analysis 208 
All experiments were performed in triplicate and one way analysis of variance (ANOVA) was 209 
XVHG WR DVVHVV VWDWLVWLFDO VLJQLILFDQFH 7XNH\¶V PXOWLSOH FRPSDULson test and t-test was 210 
performed for paired comparisons. The statistical analysis was performed using Minitab 211 
software version 17. A value of p< 0.05 was considered to be statistically significant. Graphs 212 
were produced using OriginPro 2015. 213 
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3. Results and Discussion 215 
NISV composed of MPG:Chol:DCP at a molar ratio of 50:40:10 were prepared using 216 
microfluidic mixing by changing the aqueous media used in formulating the particles. The 217 
production of NISV through microfluidic mixing is based on rapid and controlled mixing of 218 
two miscible fluids (aqueous and solvent) in a microchannel [25]. The objective of this work 219 
was to assess the effects of the aqueous media on the physicochemical properties of the 220 
resultant particles.  Five different hydration media were studied.   221 
3.1 Effect of hydration buffer on the particles size and PDI 222 
Changing the hydration media altered the size of the NISV significantly (Figure 1). The 223 
smallest particles were formed using Tris, followed by DW and HEPES with particle sizes of 224 
60.96 ±0.36 nm (p < 0.05), 71.83 ± 0.44 nm (p < 0.05), and 74.10 ± 0.51 nm (p < 0.05), 225 
respectively. The largest particle size was obtained with NS (168.40 ± 2.26 nm, p < 0.05) 226 
followed by PBS (166.10 ± 1.23 nm, p < 0.05). The PDI of these particles showed that all the 227 
formulations, had a narrow size distribution with values of 0.027 ± 0.003 (NS), 0.054 ± 0.010 228 
(PBS), 0.060 ± 0.030 (Tris), 0.091 ± 0.010 (HEPES) and 0.180 ± 0.010 for DW with the value 229 
of PDI for particles prepared with DW that was significantly different than the others (p < 230 
0.05).  This difference in the particle sizes could be attributed to the ion components of each 231 
media. NS and PBS showed similar sizes, while DW, HEPES and Tris were grouped together. 232 
The similarity between PBS and NS could be attributed to the NaCl ions, which are the major 233 
component in both buffers [38]. HEPES and Tris buffers and DW resulted in smaller particles, 234 
but within the same range, so the effects of the ionic components of the HEPES and Tris might 235 
have no significant effects as the sizes from both buffers were close to the particles prepared 236 
with DW. In drug delivery, small particle sizes (<200 nm) are preferred for drug permeability 237 
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and tumour targeting as nanoparticles in this size range tend to accumulate passively in tissues 238 
with leaky or abnormal architecture blood vessels (i.e. tumour and inflamed tissues) after 239 
intravenous administration in a phenomenon known as enhanced permeability and retention 240 
(EPR) [39]. Moreover, it has been reported that larger particles are more rapidly removed from 241 
the circulation than smaller particles due to the lower uptake by the reticuloendothelial system 242 
(RES) of smaller particles [40]. He et al. reported that in vitro macrophage uptake of larger 243 
particles was higher compared with smaller counterparts [41]. These factors directly affect the 244 
biodistribution and circulation time of NISV [42]. Therefore, the size of the NISV has 245 
significant implications on their efficacy when used as a drug delivery system. Here, although 246 
the aqueous buffers resulted in different sizes, the formulations were all below 200 nm, which 247 
makes them suitable for tumour-targeted drug delivery. 248 
 249 
Figure 1: Size and PDI of NISV prepared using microfluidics with five different hydration 250 
media. The data represents the mean ± SD (n=3) as measured by DLS, **p <0.05 indicates 251 
significant difference in size compared with the DW formulation. 252 
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3.2. The effect of the hydration media on the charge of the resultant NISV 253 
Particles prepared with DW had the highest absolute value of zeta potential (-76.83 ± 0.81 mV) 254 
followed by the particles prepared with Tris (-57.4 ± 3.33 mV), HEPES (-51.87 ± 1.18 mV), 255 
NS (-33.2 ± 2.46 mV) and PBS (-30.63 ± 2.06 mV) as shown in Figure 2. The effect of the 256 
hydration media on the total charge of the resultant particles could also be attributed to the ions 257 
present in the buffers. The surface charge of NISV gives rise to electrostatic repulsion among 258 
the nanoparticles, improving the stability of the dispersion system [43]. Zeta potential is an 259 
important factor that confers stability on the nanoparticles and higher values ensure that the 260 
particles will repel each other and resist aggregation [44]. Particles with zeta potential values 261 
that are < í mV or >+30 mV would both be stable dispersions as these values are considered 262 
high enough to prevent particle aggregation [43]. Although each of the media examined 263 
resulted in particles with different charge, all of them had a zeta potential < í mV, which 264 
means that they would be stable regardless of the type of the aqueous media used in their 265 
preparation.  266 
 267 
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 268 
Figure 2: ZP for NISV prepared with microfluidics using five different aqueous media. The 269 
data represents the mean ± SD (n=3) measured by DLS, **p <0.05 indicates significant 270 
difference in size compared with the DW formulation. 271 
3.3 Stability of NISV at different storage temperatures 272 
Vesicle stability was assessed by monitoring changes in size (Figure 3) and PDI (data not 273 
shown) of the particles over time, to predict their swelling, aggregation or precipitation 274 
characteristics. For NISV prepared with DW, the particle size showed a slight decrease in the 275 
first two weeks and then remained stable throughout the study when stored at 4, 25, and 37 °C 276 
with no significant change in the particle size (p >0.05). However, for the particles stored at 277 
50°C, there was a significant (p < 0.05) increase in the particle size during the study, which 278 
increased from 71.8 ± 0.4 nm at time zero to 101.1 ± 0.4 nm at the end of the study. NISV 279 
prepared with HEPES buffer was stable at the four different temperatures with no significant 280 
(p >0.05) increase in particle size during the study. NISV prepared with NS were stable in 281 
terms of size and PDI when stored at 4°C with no significant (p >0.05) change. When these 282 
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particles were stored at 25 and 37°C, they showed an increase in size during the first week and 283 
then remained stable for the rest of the storage duration. However, NISV prepared with NS and 284 
stored at 50°C increased significantly (p < 0.05) in size from 168.4 ± 2.26 to 208.77 ± 1.89 nm 285 
at the end of the study with no significant (p >0.05) increase in the PDI. Particles prepared with 286 
PBS remained stable with no significant (p >0.05) change in the particle size regardless of the 287 
storage temperature. For NISV prepared using Tris buffer, the particles remained stable at 4 288 
and 25°C with no significant (p >0.05) change in particles size. When these particles were 289 
stored at 37 °C, the size increased significantly (p < 0.05) in the first week from 60.69 ±0.36 290 
nm to 66.84 ± 0.14 nm and then remained stable for the rest of the storage duration. For 291 
particles prepared with Tris and stored at 50 °C, there was a significant (p < 0.05) increase in 292 
particles size from 60.96 ±0.36 to 76.18 ± 0.39 nm at the end of the storage. These stability 293 
results of the formed particles showed that the type of the hydration media used to prepare the 294 
NISV might have an effect on particle stability. This effect has been shown to be more obvious 295 
at elevated temperatures. All the formulations were stable at 4, 25, and 37 °C with no change 296 
in the particles size and PDI. At 50°C storage conditions, the particles prepared with DW, NS, 297 
and Tris increased significantly in terms of size. At elevated temperatures, lipid vesicles 298 
undergo a phase transition which affects their permeability and increase the fluidity of the lipid 299 
bilayers [30]. Different studies have reported the effects of the temperature and the dispersion 300 
media on nanoparticle stability. Some consider the increase in the temperature as an energy 301 
iQSXW DWWULEXWLQJ WKLV HIIHFW WR WKH FKDQJH LQ WKH FU\VWDOOLQH VWUXFWXUH RQ WKH SDUWLFOHV¶302 
components or zeta potential which might affect the particle size during storage [45, 46]. 303 
 304 
 305 
 306 
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 324 
Figure 3: Stability of NISV prepared with microfluidics using five different hydration media, 325 
stored at 4, 25, 37 and 50 °C. The data represents the mean ± SD (n=3) measured by DLS.  326 
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3.4 SEM imaging of NISV  327 
The morphology of the NISV was analysed by scanning electron microscopy (Figure 4). NISV 328 
were shown to have an almost spherical shape as seen in some of the images and apparent 329 
smooth surface regardless of the media used in their preparation. The SEM images confirmed 330 
the differences in the sizes between the particles (Figure 4). Figure 4E showed some non-331 
spherical large aggregates as a result of the high concentration of the particles being examined.  332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
International Journal of Pharmaceutics 
 
17 
 
Figure 4. Representative scanning electron micrographs of NISV prepared with (A) HEPES, 348 
(B) Tris, (C) DW, (D) NS and (E) PBS (Magnification ×40,000).  Salt crystals were observed 349 
in the NS micrograph as a cuboid structures (figure 4 D). Figure 4 (E) showed some large non 350 
spherical aggregates as a result of the high concentration of the particles examined.  351 
3.5 HPLC analysis of NISVS prepared with different hydration media 352 
The total Chol content in the NISV formulations was measured using HPLC. Figure 5 shows a 353 
typical standard curve and the total Chol concentration calculated from it for each formulation 354 
shown in Figure 6. The theoretical Chol concentration was 129.05 µg/ml and it was expected 355 
that the concentration post-preparation to be close to this. However, after preparation using 356 
different media, the calculated concentrations were significantly (p <0.05) lower than the 357 
theoretical one for particles prepared with HEPES, PBS, NS and DW. Only particles prepared 358 
with Tris buffer had a cholesterol concentration that was not significantly (p >0.05) different 359 
from the theoretical one. For particles prepared with PBS and NS, the Chol concentrations were 360 
close to each other with no significant (p >0.05) difference in the calculated concentration. 361 
Moreover, the concentration for NISV prepared with HEPES and DW was almost the same for 362 
both formulations with no significant (p >0.05) difference and this is the same for the particle 363 
size for these two formulations. This indicates that the type of hydration media had a significant 364 
effect on the apparent Chol concentration recovered. It is worth noting that the Chol 365 
concentration was calculated based on the AUC at the retention time of 1.55 min, but there 366 
were some peaks just before and after this time (data not shown) and this might explain the 367 
difference between the theoretical and actual concentration after preparation as we expect that 368 
some interaction occurred between cholesterol and the ions in the buffers that resulted in 369 
different separation times. We are currently studying these effects and the possible interaction 370 
between the NISV components and the different ions that form each hydration media.  371 
 372 
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 373 
Figure 5. Cholesterol standard curve prepared by measuring the AUC of various cholesterol 374 
concentrations as measured by HPLC. 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
Figure 6. Calculated cholesterol concentrations after preparing NISV with microfluidics using 383 
different hydration media compared to the theoretical concentration. The data represents the 384 
mean ± SD (n=3) measured by HPLC, **p <0.05 significant decrease in Chol concentration 385 
compared with the theoretical concentration.  386 
 387 
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3.6 Turbidity assay 390 
The interaction of the different NISV with FBS was then examined in an attempt to predict the 391 
stability of these particles when exposed to physiological conditions by calculating the RT of 392 
each formulation when incubated with 10% (v/v) FBS. The turbidity assay measures the degree 393 
of light scattering through a sample with suspended particles. Turbidity depends mainly on the 394 
concentration of the suspended particles, the size distribution of the particles in the liquid phase 395 
and the difference in the refractive index between the particles and the suspending medium [47, 396 
48]. Microbiological instability or increase in the particle size of the suspended particles as a 397 
result of aggregation will result in an increase in the RT of the liquid [46]. All the NISV showed 398 
good stability in terms of RT over two hours at 37°C (Figure 7). This can be seen with the 399 
minimal increase of the RT for all formulations with time, bearing in mind that this increase 400 
was not significant (p >0.05). This result suggests that all the aqueous media used to prepare 401 
the NISV were effective in preventing particle aggregation when incubated with 10% (v/v) 402 
FBS.  403 
 404 
Figure 7. Relative turbidity (RT) of the NISV prepared with PBS, NS, HEPES, Tris and DW 405 
and incubated at 37°C with 10% v/v FBS. The data represents the mean ± SD (n=3). 406 
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3.7 Cytotoxicity studies 407 
Finally, we studied the formulations on the viability of two cancer cell lines (A375, A2780) 408 
and a normal PNT2 cell line. Figure 8 shows the cytotoxicity of the formulations on the cells 409 
and Table 2 shows the calculated EC50. Cell viability measurements showed that regardless of 410 
the media used to prepare the NISV, all the cell lines were 100% viable at a total lipid 411 
concentration of 78.1 µg/ml and below. We observed a media-dependent toxicity on the A375 412 
cell line. The type of the media used to prepare the particles had a significant (p <0.05) effect 413 
on the viability of these cells as there was a significant difference between the EC50 of each 414 
formula. When the media alone was tested on these cells, they were not toxic and the cells were 415 
100% viable (data not shown). The media-dependent toxicity on the A375 cells was probably 416 
due to the difference in the particle size or surface charge in each formulation which would 417 
affect its cellular uptake and the subsequent impact on viability [41]. Moreover, it has been 418 
reported that the particle size, shape and surface chemistry all have effects on cellular 419 
internalisation and intracellular trafficking [49]. Since each formulation resulted in different 420 
particle characteristics in term of size and charge, this might be the reason for the difference in 421 
the cell viability for the A375 cells. Different cell types have different sensitivities and 422 
nanomaterial interactions with cells depends on the colloidal forces and the dynamic 423 
biophysicochemical interactions between the cells and the particles [50]. These effects of the 424 
type of the hydration media used for particles preparation on the cellular viability needs to be 425 
investigated more extensively and consideration given to this phenomenon by researchers. For 426 
the other cell lines (A2780 and PNT2), although there were differences between the EC50 for 427 
each formulation, they were not significant and the EC50 for each formulation was close to the 428 
others, taking into consideration that the media alone were not toxic to any of these cell lines.  429 
 430 
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 446 
 447 
Figure 8. Figure 8 cytotoxicity of the NISV prepared with PBS, NS, HEPES, Tris and DW on 448 
(A) A375, (B) A2780 and (C) PNT2 cell lines. The data represents the mean ± SD (n=3). 449 
 450 
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 452 
4. Conclusion 453 
In this paper, we report for the first time that the aqueous media used to prepare NISV by 454 
microfluidics had a significant effect on the physiochemical characteristics of the resultant 455 
particles. These findings provide strong evidence that the type of the media used to prepare 456 
NISV by microfluidics has significant effects on particle size, distribution and surface charge. 457 
The type of the media used should be taken into consideration in order to modulate these 458 
characteristics of the formed particles. This is an important factor that will also have 459 
implications with respect to the entrapped material as the media can be chosen based on the 460 
compatibility with the intended drug to be encapsulated which in addition may help to design 461 
vesicles for different uses based on changing the preparation medium. Our future aim is to use 462 
NISV to therapeutically target cancer cells, therefore, establishing cytotoxicity of the drug 463 
delivery system alone and effect of the preparation media on the NISV cytotoxicity, while the 464 
media wee not cytotoxic on their own was also an important finding. 465 
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